Last reviewed · How we verify
Calderasib OCT
At a glance
| Generic name | Calderasib OCT |
|---|---|
| Also known as | MK-1084 OCT |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calderasib OCT CI brief — competitive landscape report
- Calderasib OCT updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI